Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Dermatologic 1

Conditions

Melanoma 2Pain 1Osteosarcoma 1Lymphoma 1Endocrine Gland Neoplasms 1Depression 1Anxiety Disorders 1

Interventions

Cyclophosphamide 6pembrolizumab 3Filgrastim 3fludarabine 2Nivolumab 2Mesna 2Ipilimumab 2Ifosfamide 2Gemcitabine 2Etoposide 2Docetaxel 2Cryosurgery 2Carboplatin 2tocilizumab 1tipifarnib 1tanespimycin 1poly ICLC 1montanide ISA 51 1lorukafusp alfa 1humanized 3F8 anti-GD2 monoclonal antibody 1fludarabine phosphate 1flt3 ligand protein 1entinostat 1dostarlimab 1cc-486 1X-Rays 1Thrombopoietin 1Therapeutics 1Thalidomide 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Osteosarcoma × Psilocybin × Dermatologic × Clear all
NCT06416085 2026-03-05

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer

University Health Network, Toronto

Phase 2 Active not recruiting
15 enrolled
DermatologicLymphoidSarcoma

Endocrine Gland Neoplasms, Lymphoma, Melanoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡